公开(公告)号：US12220403B2

公开(公告)日：2025-02-11

申请号：US18484334

申请日：2023-10-10

Applicant: ASTRAZENECA AB ,  Array BioPharma, Inc.

Inventor： Nicola Frances Bateman ,  Paul Richard Gellert ,  Kathryn Jane Hill

IPC: A61K31/4184 ,  A61K9/00 ,  A61K9/14 ,  A61K9/48 ,  A61K47/22 ,  A61K47/36 ,  C07D235/06

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

公开(公告)号：US20250011304A1

公开(公告)日：2025-01-09

申请号：US18709091

申请日：2022-12-02

Applicant: Array BioPharma Inc.

Inventor： Connor James COWDREY

IPC: C07D403/12 ,  A61K9/20 ,  A61K31/4184 ,  A61K31/517 ,  A61K45/06

Abstract: This invention relates to a crystalline form of N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, pharmaceutical compositions comprising said crystalline form, and methods of using said crystalline form in the treatment of BRAF-associated diseases and disorders, such as BRAF-associated tumors.

公开(公告)号：US20240034733A1

公开(公告)日：2024-02-01

申请号：US18034852

申请日：2021-11-02

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Matthew Arnold Marx ,  John David Lawson ,  Patrick Michael Doerner Barbaur ,  James Francis Blake ,  Jay Bradford Fell ,  John Peter Fischer ,  Bradley J. Newhouse ,  Phong Nguyen ,  Jacob M. O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Tony Pisal Tang

IPC: C07D471/08 ,  C07D519/00 ,  C07D403/12

CPC classification number: C07D471/08 ,  C07D519/00 ,  C07D403/12

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11851434B2

公开(公告)日：2023-12-26

申请号：US17514684

申请日：2021-10-29

Applicant: Array BioPharma Inc.

Inventor： Steven W. Andrews ,  James F. Blake ,  Julia Haas ,  Yutong Jiang ,  Gabrielle R. Kolakowski ,  David A. Moreno ,  Li Ren ,  Shane M. Walls

IPC: A61K31/4985 ,  C07D487/04

CPC classification number: C07D487/04

Abstract: Provided herein are compounds of the Formula I:




and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

公开(公告)号：US20230357277A1

公开(公告)日：2023-11-09

申请号：US18027300

申请日：2021-09-21

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  Shelley Allen ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Michael Christopher Hilton ,  Dean Russell Kahn ,  Macedonio Junior Mejia ,  Phong Nguyen ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Yu Savechenkov ,  Tony Pisal Tang

IPC: C07D519/00 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230339976A1

公开(公告)日：2023-10-26

申请号：US18020013

申请日：2021-08-03

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  John David Lawson ,  Shelley Allen ,  Patrick Michael Barbour ,  James Francis Blake ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Sherif Hosam Hassanien ,  Michael Christopher Hilton ,  Macedonio Junior Mejia ,  Jacob Matthew O’Leary ,  Tony Pisal Tang

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D519/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：USRE49556E1

公开(公告)日：2023-06-20

申请号：US17376199

申请日：2021-07-15

Applicant: Array BioPharma Inc.

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: A61K31/506 ,  A61K9/00 ,  A61K31/4184 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14

CPC classification number: A61K31/506 ,  A61K9/0053 ,  A61K31/4184 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  A61K31/506 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：US11504370B2

公开(公告)日：2022-11-22

申请号：US16402068

申请日：2019-05-02

Applicant: Array BioPharma Inc.

Inventor： Patrice A. Lee ,  Shannon L. Winski ,  Kevin Koch

IPC: A61K31/517 ,  A61P35/04 ,  A61P35/00 ,  A61K31/337 ,  A61K31/7068 ,  A61K45/06

Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

公开(公告)号：US11472802B2

公开(公告)日：2022-10-18

申请号：US16962305

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： Shane M. Walls ,  Li Ren ,  Ginelle A. Ramann ,  David A. Moreno ,  Andrew T. Metcalf ,  Elizabeth A. McFaddin ,  Gabrielle R. Kolakowski ,  James F. Blake ,  Donghua Dai ,  Julia Haas ,  Yutong Jiang ,  Dean Kahn

IPC: C07D471/04 ,  A61P35/00 ,  C07F9/6561

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

公开(公告)号：US20220087982A1

公开(公告)日：2022-03-24

申请号：US17313312

申请日：2021-05-06

Applicant: AstraZeneca AB ,  Array BioPharma, Inc.

Inventor： Nicola Frances BATEMAN ,  Paul Richard GELLERT ,  Kathryn Jane HILL

IPC: A61K31/4184 ,  A61K9/14 ,  A61K9/48 ,  C07D235/06 ,  A61K47/36 ,  A61K9/00 ,  A61K47/22

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.